Search

Your search keyword '"Lattanzio, R."' showing total 329 results
Start Over Author "Lattanzio, R." Language english
329 results on '"Lattanzio, R."'

2. P128 - Surveillance interruption and need for active treatment in Von Hippel-Lindau disease: implications for clinical management and trial design

Author

Cei, F., Re, C., Belladelli, F., Salerno, L., Falini, A., Calloni, S., De Cobelli, F., Guazzarotti, G., Mortini, P., Capitanio, J.F., Bailo, M., Bandello, F., Lattanzio, R., Falconi, M., Partelli, S., Muffatti, F., Castellino, L., Piccioni, L.O., Battista, R.A., Rowe, I., Montorsi, F., Capitanio, U., Larcher, A., and Salonia, A.

Published
2024
Full Text
View/download PDF

6. The outcome of fluocinolone acetonide intravitreal implant is predicted by the response to dexamethasone implant in diabetic macular oedema

Author

Cicinelli, M.V. Rosenblatt, A. Grosso, D. Zollet, P. Capone, L. Rabiolo, A. Lattanzio, R. Loewenstein, A. Bandello, F. Nassisi, M. Tan, A. Reynolds, R. Singh, S.R. Vaezi, K.P. Giocanti-Aurégan, A. Weinberg, T. Faes, L. Schwartz, R. Reyes, D.Y.A. Savastano, A. Touhami, S. Garcia, H.R. Pohlmann, D. Plant, A. Ventura, C.V. Chatziralli, I. Phasukkijwatana, N. Ruiz-Medrano, J. Yuan, M. Yılmaz, İ. Vogt, D. Ting, D.S.W. Mustapha, M. Mendaro, M. On behalf of the International Retina Collaborative

Subjects
genetic structures, polycyclic compounds, sense organs, hormones, hormone substitutes, and hormone antagonists, eye diseases
Abstract

Background/Objectives: To investigate if the visual and anatomic response to the first dexamethasone implant (DEX) predicts the 12-month clinical outcome after shifting to fluocinolone acetonide (FAc) implant in patients with diabetic macular oedema (DMO). Methods: Retrospective cohort study including pseudophakic patients with previously treated DMO, undergone one or more DEX injections before FAc. Functional and morphologic response to DEX was defined based on the best-corrected visual acuity (BCVA) and central macular thickness (CMT) changes after the first DEX, respectively. Steroid-response was defined as intraocular pressure (IOP) elevation ≥5 mmHg or IOP > 21 mmHg after any previous DEX exposure. Pairwise comparisons for BCVA, CMT, and IOP after FAc were performed with linear mixed models and a repeated-measure design. Results: Forty-four eyes of 33 patients were included. Patients were shifted to FAc after a mean ± standard deviation of 4.6 ± 3.2 DEX injections. Overall, BCVA and CMT improved during the first 12 months after switching to FAc (p = 0.04 and p < 0.001, respectively). Only eyes with a good morphologic response to DEX had a significant CMT reduction after FAc (p < 0.001), while no significant relationship was found between BCVA improvement after DEX and after FAc. IOP elevation occurred in 9 eyes (20%) following DEX implant. These eyes carried a 20-fold increased risk of having an IOP rise after FAc (p < 0.001), with a non-linear relationship between the IOP increase after DEX and the one after FAc. Conclusion: The response to previous DEX may anticipate the morphologic response to subsequent FAc. Eyes with steroid-induced IOP elevation after DEX are at a high risk of IOP increase after FAc. The visual response after FAc was not associated with the visual response to previous steroids, indicating that FAc may have a role also in patients refractory to DEX implant. © 2021, The Author(s), under exclusive licence to The Royal College of Ophthalmologists.

Published
2021

7. Randomised clinical trial: mesalazine and/or probiotics in maintaining remission of symptomatic uncomplicated diverticular disease – a double-blind, randomised, placebo-controlled study

Author

Tursi, A., Brandimarte, G., Elisei, W., Picchio, M., Forti, G., Pianese, G., Rodino, S., DʼAmico, T., Sacca, N., Portincasa, P., Capezzuto, E., Lattanzio, R., Spadaccini, A., Fiorella, S., Polimeni, F., Polimeni, N., Stoppino, V., Stoppino, G., Giorgetti, G. M., Aiello, F., and Danese, S.

Published
2013
Full Text
View/download PDF

8. Effects of topically administered neuroprotective drugs in early stages of diabetic retinopathy: Results of the EUROCONDOR clinical trial

Author

Simo, Rafael, Hernandez, Cristina, Porta, Massimo, Bandello, Francesco, Grauslund, Jakob, Harding, Simon P, Aldington, Stephen J, Egan, Catherine, Frydkjaer-Olsen, Ulrik, Garcia-Arumi, Jose, Gibson, Jonathan, Lang, Gabriele E, Lattanzio, Rosangela, Massin, Pascale, Midena, Edoardo, Ponsati, Berta, Ribeiro, Luisa, Scanlon, Peter, Lobo, Conceicao, Costa, Miguel Angelo, Cunha-Vaz, Jose, Garcia-Ramirez, M, van Reck, E, Gil, E, Morillas, M, Cunha-Vaz, J, Ribeiro, L, Lobo, C, Costa, MA, Nunes, S, Figueira, J, Pereira-Marques, I, Neves, C, Schwartz, C, Porta, M, Trento, M, Durando, O, Merlo, S, Bandello, F, Lattanzio, R, Zucchiatti, I, Grauslund, J, Frydkjaer-Olsen, U, Harding, SP, Scanlon, P, Aldington, SJ, Jones, V, Johnson, L, Carter, S, Spurway, J, Egan, C, Esposti, S, Leitch-Devlin, L, Rocco, V, Rees, A, Garcia-Arumi, J, Zapata, MA, Boixadera, A, Macia, C, Distefano, L, Torrent, T, Casals, F, de Dios, N, Gibson, J, Lang, GE, Jens-Ulrich, W, Christian, E, Adnan, K, Massin, P, Erginay, A, Midena, E, Vujosevic, S, Pilotto, E, Longhin, E, Convento, E, Ponsati, B, Fernandez-Carneado, J, Arrastia-Casado, S, Orgue, S, Ramirez-Lamelas, DT, Almazan-Moga, A, Salva, A, Riera, L, Treatme, European Consortium Early, Simo, R., Hernandez, C., Porta, M., Bandello, F., Grauslund, J., Harding, S. P., Aldington, S. J., Egan, C., Frydkjaer-Olsen, U., Garcia-Arumi, J., Gibson, J., Lang, G. E., Lattanzio, R., Massin, P., Midena, E., Ponsati, B., Ribeiro, L., Scanlon, P., Lobo, C., Costa, M. A., and Cunha-Vaz, J.

Subjects
0301 basic medicine, medicine.medical_specialty, Endocrinology, Diabetes and Metabolism, Administration, Topical, Population, 030209 endocrinology & metabolism, Type 2 diabetes, Placebo, law.invention, 03 medical and health sciences, 0302 clinical medicine, Randomized controlled trial, law, Internal medicine, Diabetes mellitus, Internal Medicine, medicine, Diabetes Mellitus, Humans, education, Aged, education.field_of_study, Diabetic Retinopathy, business.industry, Brimonidine, Brimonidine Tartrate, Diabetes Mellitus, Type 2, Middle Aged, Neuroprotective Agents, Somatostatin, Diabetic retinopathy, medicine.disease, 030104 developmental biology, Topical, Administration, business, Type 2, medicine.drug
Abstract

The primary objective of this study was to assess whether the topical administration of two neuroprotective drugs (brimonidine and somatostatin) could prevent or arrest retinal neurodysfunction in patients with type 2 diabetes. For this purpose, adults aged between 45 and 75 years with a diabetes duration ≥5 years and an Early Treatment of Diabetic Retinopathy Study (ETDRS) level of ≤35 were randomly assigned to one of three arms: placebo, somatostatin, or brimonidine. The primary outcome was the change in implicit time (IT) assessed by multifocal electroretinography between baseline and at the end of follow-up (96 weeks). There were 449 eligible patients allocated to brimonidine (n = 152), somatostatin (n = 145), or placebo (n = 152). When the primary end point was evaluated in the whole population, we did not find any neuroprotective effect of brimonidine or somatostatin. However, in the subset of patients (34.7%) with preexisting retinal neurodysfunction, IT worsened in the placebo group (P < 0.001) but remained unchanged in the brimonidine and somatostatin groups. In conclusion, the topical administration of the selected neuroprotective agents appears useful in preventing the worsening of preexisting retinal neurodysfunction. This finding points to screening retinal neurodysfunction as a critical issue to identify a subset of patients in whom neuroprotective treatment might be of benefit.

Published
2019
Full Text
View/download PDF

17. SC250 - The risk of Von Hippel Lindau disease according to individual sporadic cancer in a multidisciplinary program: external validation of the VHL alliance guidelines for genetic referral

Author

Larcher, A., Fallara, G., Rowe, I., Belladelli, F., Iliopoulos, O., Doglioni, C., Lucianò, R., Casari, G., Carrera, P., Patricelli, M.G., Falini, A., De Cobelli, F., Mortini, P., Capitanio, J., Bailo, M., Bandello, F., Lattanzio, R., Falconi, M., Partelli, S., Muffatti, F., Necchi, A., Montorsi, F., Capitanio, U., and Salonia, A.

Published
2022
Full Text
View/download PDF

18. A1106 - The risk of Von Hippel-Lindau disease according to individual sporadic cancer in a multidisciplinary program: External validation of the VHL Alliance guidelines for genetic referral

Author

Larcher, A., Fallara, G., Rowe, I., Belladelli, F., Iliopoulos, O., Doglioni, C., Lucianò, R., Casari, G., Carrera, P., Patricelli, M.G., Falini, A., De Cobelli, F., Mortini, P., Capitanio, J., Bailo, M., Bandello, F., Lattanzio, R., Falconi, M., Partelli, S., Muffatti, F., Necchi, A., Montorsi, F., Capitanio, U., and Salonia, A.

Published
2022
Full Text
View/download PDF

22. Intravitreal Steroids in Diabetic Macular Edema

Author

Lattanzio R., Cicinelli M. V., Bandello F., Lattanzio, R., Cicinelli, M. V., and Bandello, F.

Subjects
Diabetic Retinopathy, Intravitreal Injections, Visual Acuity, Humans, Glucocorticoids, Macular Edema
Abstract

Over the past decade, great strides have been made in the management of diabetic macular edema (DME). Therapeutic alternatives now include focal/grid laser photocoagulation, vitreo-retinal surgery, and intraocular injection of anti-angiogenic and steroid molecules. Intravitreal administration of steroids represents a fundamental alternative for recalcitrant and naive eyes with DME, especially in those cases when anti-vascular endothelial growth factor (VEGF) agents are contraindicated or a treatment regimen with fewer intravitreal injections is required. Currently, 3 intravitreal corticosteroid options for DME treatment are available: the dexamethasone delivery system, the fluocinolone acetonide insert, and off-label intravitreal triamcinolone acetonide. All 3 agents are associated with risk of cataract progression and intraocular pressure elevation, but they maintain a good safety profile. In patients who remain unresponsive to anti-VEGF therapy, are pseudophakic, at low risk for glaucoma, or who have significant cardiovascular risk, treatment with long-lasting intraocular steroids is suggested. There still remain many unanswered questions about intravitreal drugs, regarding dose, frequency, the correct regimen of each treatment, and the potential long-term side effects.

Published
2017

23. Trop-2 activates a dormant Na+/K+-ATPase/PKC alpha/CD9/ezrin signaling axis to override the basal growth program of cancer cells

Author

Trerotola, M, Relli, V, Tripaldi, R, Sacchetti, A, Havas, K, Simeone, P, Guerra, E, Aloisi, A, La Sorda, R, Lattanzio, R, Vergara, D, Fournier, I, Salzet, M, Piantelli, M, Alberti, S, Trerotola, M, Relli, V, Tripaldi, R, Sacchetti, A, Havas, K, Simeone, P, Guerra, E, Aloisi, A, La Sorda, R, Lattanzio, R, Vergara, D, Fournier, I, Salzet, M, Piantelli, M, and Alberti, S

Published
2017

24. SC311 - External validation of the VHL alliance guidelines for VHL genetic testing in patients diagnosed with renal cell carcionoma

Author

Larcher, A., Rowe, I., Fallara, G., Romani, M., Colandrea, G., Doglioni, C., Lucianò, R., Casari, G., Carrera, P., Patricelli, M.G., Falini, A., Calloni, S., De Cobelli, F., Guazzarotti, G., Mortini, P., Capitanio, J., Bandello, F., Lattanzio, R., Falconi, M., Partelli, S., Necchi, A., Raggi, D., Montorsi, F., Capitanio, U., and Salonia, A.

Published
2021
Full Text
View/download PDF

25. P0636 - External validation of the VHL alliance guidelines for VHL genetic testing in patients diagnosed with renal cell carcionoma

Author

Larcher, A., Rowe, I., Fallara, G., Romani, M., Doglioni, C., Lucianò, R., Casari, G., Carerra, P., Patricelli, M.G., Falini, A., Calloni, S., De Cobelli, F., Guazzarotti, G., Mortini, P., Capitanio, J., Bandello, F., Lattanzio, R., Falconi, M., Partelli, S., Necchi, A., Raggi, D., Montorsi, F., Capitanio, U., and Salonia, A.

Published
2021
Full Text
View/download PDF

27. Optical Coherence Tomography Angiography in Dystrophies

Author

Battaglia Parodi M., Pierro L., Gagliardi M., Lattanzio R., Querques G., Bandello F., Battaglia Parodi, M., Pierro, L., Gagliardi, M., Lattanzio, R., Querques, G., and Bandello, F.

Subjects
Adult, Choroid, Retinal Dystrophies, Angiography, Humans, Retinal Vessels, Female, Choroid Diseases, Middle Aged, Tomography, Optical Coherence
Abstract

Optical coherence tomography (OCT) angiography (OCT-A) represents an innovative imaging technique which can delineate the retinal and choroidal vascular networks. OCT-A in the assessment of chorio-retinal dystrophies reveal alterations especially located at the level of the deep capillary plexus and the choriocapillaris. This information can have a direct implication on the understanding of the pathogenesis of dystrophies and for their future therapeutic management.

Published
2016

28. Laparoendoscopic rendezvous versus ERCP in the management of cholecystocholedocholithiasis: a cohort study.

Author

Lauri, A., Rando, G., Vittorini, V., Lattanzio, R., Caterino, G., Fabiani, S., Navarra, L., Cedrone, F., and Cocomello, L.

Subjects
ENDOSCOPIC retrograde cholangiopancreatography, GALLSTONES, COHORT analysis
Abstract

This article compares two methods, laparoendoscopic rendezvous (RV) and endoscopic retrograde cholangiopancreatography (ERCP), for treating cholecystocholedocholithiasis, a condition where gallstones are associated with common bile duct stones. The study found that patients treated with RV were more likely to achieve complete resolution of the condition compared to those treated with ERCP. There were no significant differences in postprocedural complications between the two groups, although the length of hospital stay was slightly longer for the RV group. The study suggests that RV may be a more effective and cost-saving approach, especially in centers with low ERCP volume. [Extracted from the article]

Published
2024
Full Text
View/download PDF

29. Dexamethasone intravitreal implant in previously treated patients with diabetic macular edema: Subgroup analysis of the MEAD study

Author

Augustin, A. J., Kuppermann, B. D., Lanzetta, P., Loewenstein, A., X. -Y., Li, Cui, H., Hashad, Y., Whitcup, S. M., Abujamra, S., Acton, J., Ali, F., Antoszyk, A., Awh, C. C., Barak, A., Bartz-Schmidt, K. U., Baumal, C. R., Belfort, R. Jr., Bhende, M., Boyer, D. S., Bridges, W. Z. Jr., Brown, D. M., Carmichael, T., Carnevale, K., Casella, A. M., Chang, T., Chechik, D., Chen, S. -N., Chong, L. P., Chong, V., Corwin, J., Creuzot-Garcher, C., Cruess, A., Daniell, M., De Avila, M. P., De Moraes, H. V. Jr., Devenyi, R. G., Doft, B. H., Donaldson, M., Dreyer, R., Eliott, D., Engel, H. M., Ernest, J., Essman, T. F., Falcone, P. M., Fekrat, S., Ferencz, J. R., Ferreira, J. L., Figueira, J., Fiser, I., Foster, B., Fox, G. M., Freeman, W. R., Garg, S. P., Gillies, M., Glaser, D., Goldstein, B. G., Gomes, A. M. V., Gonder, J. R., Gopal, L., Gous, P., Gupta, A., Halperin, L., Han, D., Hariprasad, S. M., Holz, F. G., Kaiser, P., Kalvodova, B., Katz, B., Katz, R. S., Kecik, D., Kellaway, J., Klemperer, I., Lattanzio, R., Lee, W. -K., Lehr, J., Leys, M., Loose, I., Lotery, A., D. -W., Lu, Mccartney, P., Majji, A. B., Martinez, J. A., Massin, P., Maturi, R. K., Menchini, U., Menon, G., Michels, M., Midena, E., Miller, J. Jr., Mitchell, P., Moisseiev, J., Morse, L., Navarro, R., Nemeth, J., Newland, H., Newsom, R., Nichols, J., Orellana, J., Orzalesi, N., Paranhos, A. Jr., Park, R., Park, S., Parodi, M. B., Pavan, P. R., Peace, J., Perez-Ortiz, D. J., Pollack, A., Ramaswamy, K., Ratnakaram, R., Ravalico, G., Rehak, J., Rezaei, K., Rizzo, S., Rodriguez-Alvira, F. J., Romanet, J. -P., Rose, S., Rosen, R. B., Rossetti, L., Ruiz-Moreno, J. M., Sadda, S., Sall, K., Sandner, D., Sanz, A. F. -V., Sartani, G., Schmickler, S., Schwartz, S. D., Sharma, Y. R., Sheu, S. -J., Singer, M., Sivaprasad, S., Soubrane, G., Soucek, P., Souied, E. H., Staurenghi, G., Studnicka, J., Suarez-Figueroa, M., Takahashi, W. Y., Tognetto, D., Tsai, P. L., Ulanski, L. J., H. S., Uy, Varano, M., Veith, M., Vicha, I., Viola, F., Visser, L., Weinberger, D., Wing, G. L., Wong, E., Wong, T. Y., Wylegala, E., Yan, J., Yoon, Y. H., Young, L. H., H. G., Yu, Zimmer-Galler, I. E., Augustin, Aj, Kuppermann, Bd, Lanzetta, P, Loewenstein, A, Li, Xy, Cui, H, Hashad, Y, Whitcup, Sm, on behalf of for the Ozurdex MEAD Study, Group, Battaglia Parodi, M, Augustin, A. J., Kuppermann, B. D., Lanzetta, P., Loewenstein, A., Li, X. -Y., Cui, H., Hashad, Y., Whitcup, S. M., Abujamra, S., Acton, J., Ali, F., Antoszyk, A., Awh, C. C., Barak, A., Bartz-Schmidt, K. U., Baumal, C. R., Belfort, R., Bhende, M., Boyer, D. S., Bridges, W. Z., Brown, D. M., Carmichael, T., Carnevale, K., Casella, A. M., Chang, T., Chechik, D., Chen, S. -N., Chong, L. P., Chong, V., Corwin, J., Creuzot-Garcher, C., Cruess, A., Daniell, M., De Avila, M. P., De Moraes, H. V., Devenyi, R. G., Doft, B. H., Donaldson, M., Dreyer, R., Eliott, D., Engel, H. M., Ernest, J., Essman, T. F., Falcone, P. M., Fekrat, S., Ferencz, J. R., Ferreira, J. L., Figueira, J., Fiser, I., Foster, B., Fox, G. M., Freeman, W. R., Garg, S. P., Gillies, M., Glaser, D., Goldstein, B. G., Gomes, A. M. V., Gonder, J. R., Gopal, L., Gous, P., Gupta, A., Halperin, L., Han, D., Hariprasad, S. M., Holz, F. G., Kaiser, P., Kalvodova, B., Katz, B., Katz, R. S., Kecik, D., Kellaway, J., Klemperer, I., Lattanzio, R., Lee, W. -K., Lehr, J., Leys, M., Loose, I., Lotery, A., Lu, D. -W., Mccartney, P., Majji, A. B., Martinez, J. A., Massin, P., Maturi, R. K., Menchini, U., Menon, G., Michels, M., Midena, E., Miller, J., Mitchell, P., Moisseiev, J., Morse, L., Navarro, R., Nemeth, J., Newland, H., Newsom, R., Nichols, J., Orellana, J., Orzalesi, N., Paranhos, A., Park, R., Park, S., Parodi, M. B., Pavan, P. R., Peace, J., Perez-Ortiz, D. J., Pollack, A., Ramaswamy, K., Ratnakaram, R., Ravalico, G., Rehak, J., Rezaei, K., Rizzo, S., Rodriguez-Alvira, F. J., Romanet, J. -P., Rose, S., Rosen, R. B., Rossetti, L., Ruiz-Moreno, J. M., Sadda, S., Sall, K., Sandner, D., Sanz, A. F. -V., Sartani, G., Schmickler, S., Schwartz, S. D., Sharma, Y. R., Sheu, S. -J., Singer, M., Sivaprasad, S., Soubrane, G., Soucek, P., Souied, E. H., Staurenghi, G., Studnicka, J., Suarez-Figueroa, M., Takahashi, W. Y., Tognetto, D., Tsai, P. L., Ulanski, L. J., Uy, H. S., Varano, M., Veith, M., Vicha, I., Viola, F., Visser, L., Weinberger, D., Wing, G. L., Wong, E., Wong, T. Y., Wylegala, E., Yan, J., Yoon, Y. H., Young, L. H., Yu, H. G., and Zimmer-Galler, I. E.

Subjects
Male, Vascular Endothelial Growth Factor A, Visual acuity, Triamcinolone acetonide, genetic structures, medicine.medical_treatment, Visual Acuity, Angiogenesis Inhibitors, Drug Implant, Triamcinolone Acetonide, Dexamethasone, Immunosuppressive Agent, Glucocorticoid, Diabetic retinopathy, Dexamethasone Intravitreal Implant, Corticosteroid, Drug delivery, Implant, Macular edema, Aged, Diabetic Retinopathy, Drug Implants, Female, Glucocorticoids, Humans, Immunosuppressive Agents, Intravitreal Injections, Macular Edema, Middle Aged, Retreatment, Tomography, Optical Coherence, Ophthalmology, Tomography, General Medicine, medicine.symptom, medicine.drug, Angiogenesis Inhibitor, Human, Research Article, medicine.medical_specialty, Subgroup analysis, medicine, business.industry, Intravitreal Injection, Cataract surgery, medicine.disease, eye diseases, Optical Coherence, business
Abstract

Dexamethasone intravitreal implant 0.7 mg (DEX 0.7) was approved for treatment of diabetic macular edema (DME) after demonstration of its efficacy and safety in the MEAD registration trials. We performed subgroup analysis of MEAD study results to evaluate the efficacy and safety of DEX 0.7 treatment in patients with previously treated DME. Three-year, randomized, sham-controlled phase 3 study in patients with DME, best-corrected visual acuity (BCVA) of 34–68 Early Treatment Diabetic Retinopathy Study letters (20/200–20/50 Snellen equivalent), and central retinal thickness (CRT) ≥300 μm measured by time-domain optical coherence tomography. Patients were randomized to 1 of 2 doses of DEX (0.7 mg or 0.35 mg), or to sham procedure, with retreatment no more than every 6 months. The primary endpoint was ≥15-letter gain in BCVA at study end. Average change in BCVA and CRT from baseline during the study (area-under-the-curve approach) and adverse events were also evaluated. The present subgroup analysis evaluated outcomes in patients randomized to DEX 0.7 (marketed dose) or sham based on prior treatment for DME at study entry. Baseline characteristics of previously treated DEX 0.7 (n = 247) and sham (n = 261) patients were similar. In the previously treated subgroup, mean number of treatments over 3 years was 4.1 for DEX 0.7 and 3.2 for sham, 21.5 % of DEX 0.7 patients versus 11.1 % of sham had ≥15-letter BCVA gain from baseline at study end (P = 0.002), mean average BCVA change from baseline was +3.2 letters with DEX 0.7 versus +1.5 letters with sham (P = 0.024), and mean average CRT change from baseline was −126.1 μm with DEX 0.7 versus −39.0 μm with sham (P

Published
2015

30. OPTICAL COHERENCE TOMOGRAPHIC HYPERREFLECTIVE FOCI IN EARLY STAGES OF DIABETIC RETINOPATHY

Author

De Benedetto U, Sacconi R, Pierro L, Lattanzio R, BANDELLO , FRANCESCO, De Benedetto, U, Sacconi, R, Pierro, L, Lattanzio, R, and Bandello, Francesco

Abstract

Purpose: To analyze the presence of hyperreflective foci in Type 1 and Type 2 diabetic patients, separately, without clinically significant diabetic macular edema and visual impairment. Methods: Noninvasive, observational prospective study. Seventeen and 19 consecutive Type 1 and Type 2 diabetic patients (33 and 38 eyes), respectively, were recruited. All patients had no clinically significant diabetic macular edema or visual impairment. Two age-and sex-matched control groups were also included. Patients underwent an ophthalmologic examination including spectral domain optical coherence tomography. Hyperreflective foci were counted considering horizontal B-scan passing through the fovea. Results: On spectral domain optical coherence tomography, patients affected by Type 1 and Type 2 diabetes had a mean of 7.5 +/- 4.6 and 9.9 +/- 4.5 hyperreflective foci, respectively. Subjects of control groups had a mean of 0.9 +/- 0.8 and 1.7 +/- 1.5 hyperreflective foci, respectively. Hyperreflective foci amount was statistically different between Type 1 and Type 2 diabetic groups (P = 0.032) and significantly higher in diabetic patients than in controls (P < 0.001). Hyperreflective foci amount was significantly higher in diabetic patients with a poor quality glycometabolic control (P < 0.001 and P = 0.016) or affected by hypertension (P = 0.008). Conclusion: We reported the presence of hyperreflective foci in diabetic patients without diabetic macular edema and visual impairment. This spectral domain optical coherence tomography finding might be a useful marker for the diagnosis and the follow-up in the early stage of diabetic retinopathy.

Published
2015

34. Class II phosphoinositide 3-kinase C2β regulates a novel signaling pathway involved in breast cancer progression

Author

Chikh A, Ferro R, Jj, Abbott, Roberto Piñeiro, Buus R, Iezzi M, Ricci F, Bergamaschi D, Ostano P, Chiorino G, Lattanzio R, Broggini M, Piantelli M, Maffucci T, and Falasca M

Abstract

It is now well established that the enzymes phosphoinositide 3-kinases (PI3Ks) have a key role in the development and progression of many cancer types and indeed PI3Ks inhibitors are currently being tested in clinical trials. Although eight distinct PI3K isoforms exist, grouped into three classes, most of the evidence currently available are focused on one specific isoform with very little known about the potential role of the other members of this family in cancer. Here we demonstrate that the class II enzyme PI3K-C2β is overexpressed in several human breast cancer cell lines and in human breast cancer specimens. Our data indicate that PI3K-C2β regulates breast cancer cell growth in vitro and in vivo and that PI3K-C2β expression in breast tissues is correlated with the proliferative status of the tumor. Specifically we show that downregulation of PI3K-C2β in breast cancer cell lines reduces colony formation, induces cell cycle arrest and inhibits tumor growth, in particular in an estrogen-dependent in vivo xenograft. Investigation of the mechanism of the PI3K-C2β-dependent regulation of cell cycle progression and cell growth revealed that PI3K-C2β regulates cyclin B1 protein levels through modulation of microRNA miR-449a levels. Our data further demonstrate that downregulation of PI3K-C2β inhibits breast cancer cell invasion in vitro and breast cancer metastasis in vivo. Consistent with this, PI3K-C2β is highly expressed in lymph-nodes metastases compared to matching primary tumors. These data demonstrate that PI3K-C2β plays a pivotal role in breast cancer progression and in metastasis development. Our data indicate that PI3K-C2β may represent a key molecular switch that regulates a rate-limiting step in breast tumor progression and therefore it may be targeted to limit breast cancer spread.

Published
2016

35. Assessment of IcareONE rebound tonometer for self-measuring intraocular pressure

Author

Battaglia Parodi M, Iacono P, Campa C, La Spina C, Triolo G, Lattanzio R, Bandello F, Battaglia Parodi, M, Iacono, P, Campa, C, La Spina, C, Triolo, G, Lattanzio, R, and Bandello, F

Subjects
Adult, Male, medicine.medical_specialty, Intraocular pressure, genetic structures, Intraclass correlation, Goldmann applanation tonometry, Random order, Tonometry, Ocular, Young Adult, Ophthalmology, medicine, Humans, Prospective Studies, Intraocular Pressure, Aged, business.industry, Mean value, Reproducibility of Results, Glaucoma, General Medicine, Intra-rater reliability, Equipment Design, Middle Aged, eye diseases, Self Care, Cross-Sectional Studies, Female, Ocular Hypertension, sense organs, business, Kappa, Follow-Up Studies
Abstract

Purpose: To evaluate the precision of the IcareONE rebound tonometer, which was developed for self-measuring intraocular pressure (IOP) and to compare IcareONE measurement with Goldmann applanation tonometry (GAT). Methods: Twenty-four healthy eyes and 81 glaucomatous eyes were enrolled. IOP measurements (three times per session) with IcareONE were made in a random order by an ophthalmologist (Icare(O)) and by the subject (Icare(S)). Intraclass correlation coefficients (CCs), kappa values and mean values of IOP were compared among the two types of Icare recordings and GAT. Bland–Altman analysis was used to assess agreement between methods. Multiple regression analysis was performed to identify the subject factors that influenced the discordant measurements between IcareONE and GAT. Results: The mean value of Icare(O) and Icare(S) measurements was 13.5 ± 5.2 and 13.5 ± 5.4 mmHg, respectively, neither of which was significantly different from GAT (13.8 ± 4.4). The intrarater CC of Icare(O) and Icare(S) was 0.968 and 0.885, respectively. The intermethod CC and weighted kappa between Icare(O) and Icare(S) were 0.907 and 0.684, respectively. All pairwise correlations between the two types of IOP measurement showed coefficients of determination >0.8. Bland–Altman analysis did not show any proportional biases. Multiple regression analysis revealed that the differences between GAT and Icare(O) or Icare(S) were positively correlated with central corneal thickness (CCT) and negatively correlated with age. Conclusions: Intraocular pressure measurements with IcareONE by a physician and by the subject showed excellent agreement with GAT measurements; IcareONE measurements between a physician and the subject had high intrarater reliability, and good agreement thicker CCT led IcareONE measurement to overestimate IOP, while higher age caused it to underestimate IOP compared with GAT.

Published
2014

37. Dexamethasone intravitreal implant in previously treated patients with diabetic macular edema: Subgroup analysis of the MEAD study

Author

Augustin, AJ, Kuppermann, BD, Lanzetta, P, Loewenstein, A, Li, XY, Cui, H, Hashad, Y, Whitcup, SM, Abujamra, S, Acton, J, Ali, F, Antoszyk, A, Awh, CC, Barak, A, Bartz-Schmidt, KU, Baumal, CR, Belfort, R, Bhende, M, Boyer, DS, Bridges, WZ, Brown, DM, Carmichael, T, Carnevale, K, Casella, AM, Chang, T, Chechik, D, Chen, SN, Chong, LP, Chong, V, Corwin, J, Creuzot-Garcher, C, Cruess, A, Daniell, M, De Avila, MP, De Moraes, HV, Devenyi, RG, Doft, BH, Donaldson, M, Dreyer, R, Eliott, D, Engel, HM, Ernest, J, Essman, TF, Falcone, PM, Fekrat, S, Ferencz, JR, Ferreira, JL, Figueira, J, Fiser, I, Foster, B, Fox, GM, Freeman, WR, Garg, SP, Gillies, M, Glaser, D, Goldstein, BG, Gomes, AMV, Gonder, JR, Gopal, L, Gous, P, Gupta, A, Halperin, L, Han, D, Hariprasad, SM, Holz, FG, Kaiser, P, Kalvodova, B, Katz, B, Katz, RS, Kecik, D, Kellaway, J, Klemperer, I, Lattanzio, R, Lee, WK, Lehr, J, Leys, M, Loose, I, Lotery, A, Lu, DW, McCartney, P, Majji, AB, Martinez, JA, Massin, P, Maturi, RK, Menchini, U, Menon, G, Michels, M, Midena, E, Miller, J, Mitchell, P, Moisseiev, J, Morse, L, Navarro, R, Nemeth, J, Newland, H, Newsom, R, Nichols, J, Orellana, J, and Orzalesi, N

Subjects
genetic structures, eye diseases
Abstract

© 2015 Augustin et al. Background: Dexamethasone intravitreal implant 0.7 mg (DEX 0.7) was approved for treatment of diabetic macular edema (DME) after demonstration of its efficacy and safety in the MEAD registration trials. We performed subgroup analysis of MEAD study results to evaluate the efficacy and safety of DEX 0.7 treatment in patients with previously treated DME. Methods: Three-year, randomized, sham-controlled phase 3 study in patients with DME, best-corrected visual acuity (BCVA) of 34.68 Early Treatment Diabetic Retinopathy Study letters (20/200.20/50 Snellen equivalent), and central retinal thickness (CRT) ≥300 μm measured by time-domain optical coherence tomography. Patients were randomized to 1 of 2 doses of DEX (0.7 mg or 0.35 mg), or to sham procedure, with retreatment no more than every 6 months. The primary endpoint was ≥15-letter gain in BCVA at study end. Average change in BCVA and CRT from baseline during the study (area-under-the-curve approach) and adverse events were also evaluated. The present subgroup analysis evaluated outcomes in patients randomized to DEX 0.7 (marketed dose) or sham based on prior treatment for DME at study entry. Results: Baseline characteristics of previously treated DEX 0.7 (n = 247) and sham (n=261) patients were similar. In the previously treated subgroup, mean number of treatments over 3 years was 4.1 for DEX 0.7 and 3.2 for sham, 21.5 % of DEX 0.7 patients versus 11.1 % of sham had ≥15-letter BCVA gain from baseline at study end (P = 0.002), mean average BCVA change from baseline was +3.2 letters with DEX 0.7 versus +1.5 letters with sham (P = 0.024), and mean average CRT change from baseline was -126.1 μm with DEX 0.7 versus -39.0 μm with sham(P < 0.001). Cataract-related adverse events were reported in 70.3 % of baseline phakic patients in the previously treated DEX 0.7 subgroup; vision gains were restored following cataract surgery. Conclusions: DEX 0.7 significantly improved visual and anatomic outcomes in patients with DME previously treated with laser, intravitreal anti-vascular endothelial growth factor, intravitreal triamcinolone acetonide, or a combination of these therapies. The safety profile of DEX 0.7 in previously treated patients was similar to its safety profile in the total study population.

Published
2015
Full Text
View/download PDF

39. Diabetic Macular Edema : Juxtascleral (JS) versus Intravitreal (IV) Triamcinolone Acetonide (TA) Injections

Author

Brancato R, Lattanzio R, Tremolada G, Scotti F, Donati S, Pierro L, Introini U, Modorati G, Miserocchi E, Brancato, R, Lattanzio, R, Tremolada, G, Scotti, F, Donati, S, Pierro, L, Introini, U, Modorati, G, and Miserocchi, E

Abstract

Purpose: To evaluate the short–term efficacy of juxtascleral triamcinolone acetonide (JSTA) versus intravitreal triamcinolone acetonide (IVTA) injections on macular thickness measured by Optical Coherence Tomography (OCT) and on visual acuity (VA) in eyes affected by diffuse diabetic macular edema (DME) refractory to laser treatment. Methods: Eyes of diabetic patients affected by DME without vitreo–retinal interface anomalies are being randomized to one of the following two treatment groups: JSTA (group 1) and IVTA (group 2). All patients had normal intraocular pressure (IOP) and underwent previous laser treatment of posterior pole. At present are included in group 1 (JSTA) 9 eyes of 9 patients, and in group 2 (IVTA) 14 eyes of 14 patients. Controls (complete ophthalmological examination, OCT, fundus photographies) were scheduled at days 0, 7, 30, 90, 180. Fluorescein angiography was scheduled at days 0, 30, 90,180. The patients of group 1 that, at seven days control, showed a decrease of DME 100 µ m on OCT, underwent a second injection (JSTA). Results: Seven days after injection, macular thickness significantly decreased only in group 2 (mean thickness: – 47.5 ± 125 µ m in group 1; mean thickness: – 316.3 ± 159 µ m in group 2) while VA significantly increased in both groups (mean VA : 0.1 ± 0.21 in group 1; mean VA : 0.2 ± 0.17 in group 2). Pearson’s p was respectively – 0.2 in group 1 and – 0.3 in group 2. 5 patients of group 1, that showed a decrease of DME 100 µ m, underwent a 2nd JSTA injection. After 30 days macular thickness was significantly decreased in both groups (mean thickness : – 150.5 ± 162 µ m in group 1 and – 357.3 ± 149.4 µ m in group 2). The mean VA was 0.09 ± 0.10 in group 1 and 0.23 ± 0.17 in group 2. Pearson’s p was respectively 0.1 and 0.018. Conclusions: Both JSTA and IVTA injections can rapidly reduce DME and increase VA. IVTA appears to be more effective in short–term. Longer follow–up would enable the assessment of long–term effectiveness of both techniques.

Published
2005

40. Thymic epithelial tumors express vascular endothelial growth factors and their receptors as potential targets of antiangiogenic therapy: A tissue micro array-based multicenter study

Author

Lattanzio, R, La Sorda, R, Facciolo, F, Sioletic, S, Lauriola, L, Martucci, R, Gallo, E, Palmieri, G, Evoli, A, Alessandrini, G, Ruco, L, Rendina, Ea, Truini, M, Chiarle, Roberto, Barreca, A, Pich, Achille, Ascani, S, Remotti, D, Tunesi, G, Granone, P, Ratto, Gb, Puma, F, Pescarmona, E, Piantelli, M, Marino, M, Carlini, S, Cerasoli, V, Corzani, F, Melis, E, Filippetti, M, Canalini, P, Palestro, G, Lalle, M, Ruffini, Enrico, Ceribelli, A, Rinaldi, Mauro, and Thymic Epithelial Tumor Working Group

Subjects
Male, Vascular Endothelial Growth Factor A, Cancer Research, Pathology, Angiogenesis, Angiogenesis Inhibitors, Receptor tyrosine kinase, ANGIOGENESIS, chemistry.chemical_compound, 0302 clinical medicine, Thymoma, Thymic epithelial tumors, Biomarkers, Tissue Micro Array, Vascular endothelial growth factor, Vascular endothelial growth factor receptor, Medicine, Molecular Targeted Therapy, Neoplasms, Glandular and Epithelial, Child, Aged, 80 and over, 0303 health sciences, HISTOLOGIC CLASSIFICATION, MALIGNANT THYMOMA, BREAST-CANCER, CARCINOMAS, VEGF, INHIBITOR, OVEREXPRESSION, TOMOGRAPHY, CHALLENGES, biology, Neovascularization, Pathologic, tissue micro array, thymic epithelial tumors, vascular endothelial growth factor, biomarkers, thymoma, vascular endothelial growth factor receptor, Middle Aged, Immunohistochemistry, 3. Good health, Vascular endothelial growth factor A, Oncology, Vascular endothelial growth factor C, 030220 oncology & carcinogenesis, Female, Pulmonary and Respiratory Medicine, Adult, medicine.medical_specialty, Adolescent, Antineoplastic Agents, 03 medical and health sciences, Paracrine signalling, Young Adult, Humans, Autocrine signalling, 030304 developmental biology, Aged, Neoplasm Staging, Retrospective Studies, Settore MED/06 - ONCOLOGIA MEDICA, business.industry, Thymus Neoplasms, Receptors, Vascular Endothelial Growth Factor, chemistry, Cancer cell, Cancer research, biology.protein, business
Abstract

Objectives Tumor angiogenesis is an essential and complex process necessary for the growth of all tumors which represents a potential therapeutic target. Angiogenesis inhibitors targeting vascular endothelial growth factor (VEGF) or their receptor tyrosine kinases have been approved by the FDA. In thymic epithelial tumors (TET), targeted therapies have been sporadically applied due to their rarity. To ascertain the presence of potential therapeutic targets, we analyzed by immunohistochemistry the expression of angiogenesis-related biomarkers in a large series of TET arranged in Tissue Micro Arrays (TMA). Materials and methods We assessed by immunohistochemistry the expression of the possible molecular target of anti-angiogenic therapy, i.e. VEGFA, VEGFC, VEGFD, VEGFR1, VEGFR2, VEGFR3, and PDGFRβ, in a TMA series of 200 TET collected in the framework of a multi-institutional collaborative project for Rare Diseases. Results When compared to the low-risk tumors, high-risk TET (B2, B3, carcinomas) contained higher proportion of cancer cells expressing VEGFA, VEGFC and VEGFD ( P P P P =0.002), VEGFR2 ( P =0.013), and VEGFR3 ( P =0.041). No differences were observed in terms of PDGFRβ expression. Conclusions According to our data, it is possible to hypothesize the existence of multiple paracrine and/or autocrine loops in TET, particularly in the high-risk ones, involved in TET growth and progression. Anti-angiogenic agents, directed to inhibit these loops, are therefore to be considered as potential tools in advanced TET therapy.

Published
2014

42. A phase 2/3, multicenter, randomized, double-masked, 2-year trial of pegaptanib sodium for the treatment of diabetic macular edema

Author

Sultan, Mb, Zhou, D, Loftus, J, Dombi, T, Ice, Ks, Bird, A, D'Amico, D, Herson, J, Klein, R, Wallisch, M, de Gronckel, S, Danielson, L, Quinaz, E, Wang, K, Balbueno, S, Mikusova, B, Spiller, Hw, Cameron, P, Sawa, M, Wallace, S, Altaweel, M, Danis, R, Domalpally, A, Alexander, S, Corkery, E, Daywalt, M, Dohm, K, Endres, R, Goulding, A, Reimers, J, Susman, R, Wabers, H, Whilhelmson, T, White, J, Lim, L, Wong, T, Mitchell, P, Kralinger, M, Stur, M, Avila, M, Farah, M, Lavinsky, J, Maberly, D, Olivier, S, Rosemont, P, Dusova, J, Ernest, J, Fiser, I, Kolar, P, Rehak, J, Larsen, M, Berrod, Jp, Devin, F, Koenig Supiot, F, Massin, P, Soubrane, G, Dithmar, S, Holz, F, Joussen, A, Lappas, A, Bartz Schmidt KU, Spital, G, Wiedemann, P, Vergados, I, Azad, R, Jalali, S, Murthy, P, Nagpal, M, Bandello, F, Lanzetta, Paolo, Lattanzio, R, Menchini, U, Keunen, J, Figueira, J, Sarra, Gm, Trittibach, P, Brand, C, Talks, J, Carnevale, K, Ciulla, Ta, Connor, Tb, Elliott, D, Friberg, Tr, Garcia, Ca, Gonzalez, Vh, Gross, N, Halperin, Ls, Hudson HL 3rd, Kokame, G, Lit, E, Marcus, Dm, Patel, S, Pavan, P, Rosa, R, Sang, D, Singer, M, Varenhorst, Mp, Wells, J, Adamis, Ap, Betts, F, Burke, K, Cunningham ET Jr, Curtiss, K, Goldbaum, M, Guyer, Dr, Harrison, E, Katz, B, Liss, C, Masonson, H, O'Shaughnessy, D, Archer, R, Barbeito, R, Bojko, R, Borgstadt, M, Carlin, R, Chappell, P, Cobles, C, Culhane, J, Davisson, B, Elkins, M, Eveleth, D, Fernstrom, S, Franklin, K, Houghton, F, Edward Hume, H, Hilary Jones, J, Kirschner, K, Kwok, K, Lee, P, Littel, A, Lock, K, Lyster, S, Machado, P, Maeda Chubachi, T, Maute, A, Mulvaney, A, O'Neill, B, Paggiarino, D, Quinto Olegario, K, Pleil, A, Stewart, C, Wilson, G, Yan, E, and Zurlo, M.

Subjects
Adult, Male, Vascular Endothelial Growth Factor A, medicine.medical_specialty, Visual acuity, Fundus Oculi, Pegaptanib, Eye disease, Population, Visual Acuity, Macular Edema, law.invention, Young Adult, Randomized controlled trial, law, Ophthalmology, Evaluation of complex medical interventions Genomic disorders and inherited multi-system disorders [NCEBP 2], medicine, Pegaptanib Sodium, Humans, Macula Lutea, Fluorescein Angiography, Adverse effect, education, Aged, Aged, 80 and over, education.field_of_study, Diabetic Retinopathy, Dose-Response Relationship, Drug, business.industry, Aptamers, Nucleotide, Middle Aged, medicine.disease, Clinical trial, Treatment Outcome, Anesthesia, Intravitreal Injections, Female, medicine.symptom, business, medicine.drug
Abstract

Item does not contain fulltext PURPOSE: To confirm the safety and compare the efficacy of intravitreal pegaptanib sodium 0.3 mg versus sham injections in subjects with diabetic macular edema (DME) involving the center of the macula associated with vision loss not due to ischemia. DESIGN: Randomized (1:1), sham-controlled, multicenter, parallel-group trial. PARTICIPANTS: Subjects with DME. INTERVENTION: Subjects received pegaptanib 0.3 mg or sham injections every 6 weeks in year 1 (total = 9 injections) and could receive focal/grid photocoagulation beginning at week 18. During year 2, subjects received injections as often as every 6 weeks per prespecified criteria. MAIN OUTCOME MEASURES: The primary efficacy endpoint was the proportion gaining >/= 10 letters of visual acuity (VA) from baseline to year 1. Safety was monitored throughout. RESULTS: In all, 260 (pegaptanib, n = 133; sham, n = 127) and 207 (pegaptanib, n = 107; sham, n = 100) subjects were included in years 1 and 2 intent-to-treat analyses, respectively. A total of 49 of the 133 (36.8%) subjects from the pegaptanib group and 25 of the 127 (19.7%) from the sham group experienced a VA improvement of >/= 10 letters at week 54 compared with baseline (odds ratio [OR], 2.38; 95% confidence interval, 1.32-4.30; P = 0.0047). For pegaptanib-treated subjects, change in mean VA from baseline by visit was superior (P

Published
2011

43. Changes in vision- and health-related quality of life in patients with diabetic macular edema treated with pegaptanib sodium or sham

Author

Loftus, Jv, Sultan, Mb, Pleil, Am, Lim, L, Wong, T, Mitchell, P, Kralinger, M, Avila, M, Farah, M, Lavinsky, J, Maberly, D, Dusova, J, Ernest, J, Fiser, I, Kolar, P, Rehak, J, Larsen, M, Berrod, Jp, Devin, F, Koenig Supiot, F, Soubrane, G, Dithmar, S, Holz, F, Joussen, A, Lappas, A, Bartz Schmidt KU, Spital, G, Wiedemann, P, Vergados, I, Azad, R, Jalali, S, Murthy, P, Nagpal, M, Bandello, F, Lanzetta, Paolo, Lattanzio, R, Keunen, J, Figueira, J, Sarra, Gm, Trittibach, P, Brand, C, Talks, J, Carnevale, K, Ciulla, Ta, Connor, Tb, Elliott, D, Mahmoud, T, Friberg, Tr, Garcia, Ca, Gonzalez, Vh, Gross, N, Halperin, Ls, Hudson HL 3rd, Kokame, G, Lit, E, Marcus, Dm, Patel, S, Pavan, P, Rosa, R, Sang, D, Sell, C, Singer, M, Varenhorst, Mp, Wells, J, Adamis, Ap, Betts, F, Burke, K, Cunningham ET Jr, Curtiss, K, Goldbaum, M, Guyer, Dr, Harrison, E, Katz, B, Liss, C, Masonson, H, O'Shaughnessy, D, Archer, R, Barbeito, R, Bojko, R, Borgstadt, M, Carlin, R, Chappell, P, Cobles, C, Cobles, J, Davisson, B, Dombi, T, Elkins, M, Eveleth, D, Fernstrom, S, Franklin, K, Houghton, F, Hume, E, Ice, K, Jones, H, Kirschner, K, Kwok, K, Lee, P, Littel, A, Lock, K, Lyster, S, Machado, P, Maeda Chubachi, T, Maute, A, Mulvaney, A, O'Neill, B, Paggiarino, D, Quinto Olegario, K, Stewart, C, Wilson, G, Yan, E, Zhou, D, and Zurlo, M.

Published
2011

44. Dexamethasone Intravitreal Implant in Patients with Macular Edema Related to Branch or Central Retinal Vein Occlusion

Author

Haller, Ja, Bandello, F, Belfort R., Jr, Blumenkranz, M. S., Gillies, M, Heier, J, Loewenstein, A, Yoon, Yh, Jiao, J, Li, Xy, Whitcup, S. M., Aaberg, Tm, Abraham, P, Abujamra, S, Acton, J, Adamczyk Ludyga, A, Adenwalla, M, Agahigian, Dd, Agoas, V, Aguilar Mendoza, M, Aisenbrey, S, Alam, S, Albiani, D, Alexandrescu, B, Alfaiate, Mm, Allam, S, Almeida, Hp, Anagnoste, S, Anand, R, Anderson, N, Antoszyk, A, Armogan, N, Arnold, J, Ash, D, Atlas, Wg, Augustin, Ja, de Ávila MP, Awh, C, Azzolini, C, Babkova, B, Bakri, Sj, Banach, Mj, Barak, A, Barile, G, Barker, D, Barnard, T, Bartz Schmidt KU, Battaglia Parodi, M, Baumal, C, Bedrich, P, Beer, P, Belfort Mattos Junior, R, Bellini, L, Benner, J, Benson, W, Benz, M, Berger, B, Bergren, R, Bharadwaj, A, Bhavan, S, Bhavsar, A, Binder, S, Biondi, A, Bishop, F, Blair, N, Blinder, K, Blumenkranz, M, Bohm, A, Boldrey, Ee, Bornfeld, N, Borrillo, Jl, Boyer, D, Bradford, R, Bridges, W, Brigatti, L, Briggs, M, Brooks HL Jr, Brown, D, Browning, A, Browning, D, Brunner, S, Brunnerova, R, Bryan, Js, Brydak Godowska, J, Buettner, H, Burns, J, Burrows, Af, Busbee, B, Butner, R, Butter, J, Byrnes, G, Callahan, C, Campochiaro, P, Cano Hildalgo RA, Canziani, T, Capaccioli, K, Capone, A, Carmichael, T, Carnevale, K, Casella, Am, Casey, R, Castanheira Dinis, A, Celis, B, Chambers, R, Chang, S, Chang, Yh, Chechik, D, Chee, Sp, Chen, E, Chen, Jt, Chen, Sn, Chen, S, Cheng, B, Chiquet, C, Chong, K, Chong, Lp, Chong, V, Chou, T, Chow, V, Chrapek, O, Chu, T, Chua, J, Chun, D, Chung, Hw, Cialdini, Ap, Ciancas, E, Cihelkova, I, Cisiecki, S, Clark, W, Cleary, T, Coco, R, Codenotti, M, Cohen, Bz, Cohen, Ja, Cohen, J, Connolly, B, Conway, B, Cook, H, Cooper, B, Coors, L, Corwin, J, Costa, Jr, Cottrell, D, Couvillion, S, Craig, J, Cruess, A, Dabbs, T, Danesh, S, Davidorf, F, Davis, J, De Cilla, S, De Fazio, R, de la Fuente MA, de la Rua ER, De Mattia, M, Deen, A, Del Priore, L, Delyfer, Mn, Deuter, C, Devadason, Ds, Devenyi, R, D'Heurle, D, Dickinson, J, Doft, B, Dooner, J, Doubell, D, Downie, J, Drenser, K, Dreyer, R, D'Sousa, Y, Du, T, Duarte, L, Dubiner, Hb, Dubovy, S, Dubska, Z, Dugel, P, Dunn, W, Dusova, J, Dvorak, J, Dyer, D, Dziegielewska, K, Earl, M, Egan, C, Eichenbaum, D, Eifrig, C, Ells, A, El Shabrawi, Y, Elsherbiny, S, Engel, H, Engelbrecht, N, Ernest, J, Essex, R, Eter, N, Evans, R, Fakadej, A, Falcone, P, Fan, D, Fan, Jt, Eid Farah, M, Farah, S, Feiner, L, Feldman, Rm, Ferencz, J, Fernandez Vega Sanz, A, Ferreira, Jl, Figueira, J, Fineman, M, Fiser, I, Fish, G, Fish, Rh, Fishburne, B, Fisher, Sj, Fitzsimons, R, Flaxel, C, Fletcher, E, Flores Aguilar, M, Florez, S, Flynn, H, Fogarty, S, Folgado, A, Foster, Bs, Fox, Gm, Frambach, D, Framme, C, Fransen, S, Fraser Bell, S, Frederick, A, Freeman, W, Freisberg, L, Friedman, E, Friedman, L, Fucik, M, Fuller, Dg, Gaitan, J, Gallemore, R, Gallogly, P, Arumi, Jg, Garg, S, Garretson, B, Gastaud, P, Gaudric, A, Gawrilow, P, Gehlbach, Pl, Geyer, O, Ghuman, At, Giansanti, F, Luiz Gil, A, Gilbert, Hd, Girmens, Jf, Giubilato, A, Glacet Bernard, A, Glaser, D, Glatzer, R, Goldstein, D, Gomes, Am, Gon Yu, H, Gonçalves, Fp, Gonzales, C, Googe, J, Gopal, L, Gordon, A, Gous, P, Grand, M, Cristina, P, Magro, G, Granero Riano, M, Grassi, M, Green, J, Green, S, Gregor, Z, Gregori, N, Grizzard, Ws, Groenewald, C, Gross, Jg, Gross, Ne, Gruber, A, Grutow, G, Guillet, E, Gupta, A, Gyorgyova, D, Haas, A, Haas, K, Hadden, P, Hagemann, L, Hainsworth, D, Haivala, D, Haller, J, Halperin, L, Hamer, P, Hammer, M, Han, D, Handa, Jt, Handelman, I, Handza, J, Harder, B, Harding, S, Hariprasad, Sm, Hartley, K, Hartman, P, Hartnett, Me, Harvey, P, Hassan, T, Headon, M, Hejsek, L, Higgins, P, Hillenkamp, J, Ho, A, Ho, T, Holekamp, N, Holz, E, Holz, F, Hooper, P, Hopkins, Jj, Hoskin Mott, A, Hoskins, J, Hrisomalos, N, Hsu, J, 3rd, Hubbard B., Hudson, H, Hughes, E, Hunt, A, Hunyor, A, Hwang, T, Hwang, Jf, Ibarra, M, Incarnato, N, Inhetvin Hutter, C, Introini, U, Isaacs, T, Islam, N, Iyer, Mn, Jablonski, C, Jack, Rl, Jager, R, Jahn, C, Jao, C, Jehan, F, Jonas, J, Joseph, D, Joshi, M, Jost, B, Jurklies, B, Kaincova, I, Kaiser, P, Kaiser, R, Kalvodova, B, Kamppeter, B, Kanann, Nb, Kang, K, Katz, Rs, Kaushal, S, Kecik, D, Kellaway, J, Kelly, K, Kelly, S, Khan, J, Kherani, A, Kim, R, Kim, I, Kim, J, Kim, Jg, Kim, N, Kim, Tw, Kingsley, R, Klein, R, Klemperer, I, Kociecki, J, Korbasova, M, Korda, V, Korobelnik, Jf, Koshy, Z, Kostamaa, H, Kovach, J, Kozak, I, Kozousek, V, Krasny, J, Kreiger, A, Krivosic, V, Krug JV Jr, Kruger, L, Kunimoto, D, Kuppermann, Bd, Kurtz, R, Kuznik Borkowska, A, Lai, J, Lai, W, Lake, S, Lalwani, G, Lam, Wc, Lanning, Rc, Lanzetta, Paolo, Lara, W, Larrison, Wi, Lattanzio, R, Lavina, A, Lavinsky, J, Lazzaroni, F, Lee, E, Yong Lee, J, Lee, M, Young Lee, S, Lee, V, Leff, S, Lehr, J, Lenfesty, P, Leonard, R, Levine, A, Levitan, M, Lewis, H, Liew, S, Lim, J, Lim, R, Lin, R, Lip, Pl, Liu, J, Lobes, La, Loose, I, Lotery, A, Lottenberg, Cl, Loutchkina, D, Lu, Dw, Lubczynska, A, Lujan, B, Lyssek Boron, A, Ma, C, Ma, P, Maberley, D, Maccumber, M, Madhusudhana, Kc, Madreperla, S, Magee, M, Magolan, J, Maia Junior Ode, O, Maia, A, Majji, A, Malthieu, D, Mango, C, Marmor, M, Marques, L, Martin, D, Martinez, Ja, Massaoutis, P, Mathai, A, Mathur, R, Mattioli, S, Maturi, Rk, Mazur Michalek, I, Mcallister, I, Mccabe, F, Mccannel, Ca, Mcgimpsey, S, Mchugh, Jd, Mckibbin, M, McLean WC Jr, Mcmillan, T, Meireles, R, de Melo CS, Menchini, U, Meredith, T, Merrill, P, Mian, U, Michels, M, Midena, E, Mieler, Wf, Migliavacca, L, Miller, D, Miller, J, Mincey, G, Mitchell, P, Katsuki Mizubuti, S, Mohamed, S, Mohammed, M, Moinfar, N, Moisseiev, J, Mones, J, Montemayor Lobo, R, Montero, J, de Moraes NI, Moreira CA Jr, Morely, M, Moreno, Jm, Moron, Jt, Morrison, Vl, Morse, L, Moshfeghi, A, Moshfeghi, D, Muccioli, C, Munshi, V, Murthy, Rc, Naing, T, Nair, R, Nascimento, J, Nascimento, Vp, Nawrocka, Z, Nawrocki, J, Newell, C, Newsom, R, Nguyen, J, Nguyen, Q, Nguyen, Rl, Nichols, J, Nilanjana, D, Noguchi, B, Noorily, S, Novack, R, Novak, M, Novalis, G, O'Brien, D, Offermann, I, Oguido, Ap, Oh, K, Okruszko, A, de Oliveira TL, Oliver, S, Ong, S, Orellana, J, Orzalesi, N, O'Toole, L, Ovando, Y, Paccione, J, Pach, J, Packo, K, Packowska, Ma, Palmer, J, Palmer, H, Palombi, K, Papp, A, Paques, M, Paranhos A., Jr, Park, D, Park, Ri, Park, S, Parke, D, Parravano, M, Pastor Jimeno JC, Patel, S, Patra, S, Pavan, Pr, Pearce, I, Pecold, K, Pedio, M, Peh, Kk, Pelosini, L, Pendergast, S, Perez, Br, Perez Ortiz DJ, Perkins, S, Peters, M, Pheasant, T, Pilat, J, Pilotto, E, Piltz Seymour, J, Pirracchio, A, Pollack, A, Portella, E, Pracharova, Z, Prati, M, Prensky, Jg, Preston, R, Prieto, F, Puls, S, Purohit, Ar, Quintao, T, Rahhal, F, Rahman, W, Ramos, Ar, Ramsey, S, Rani, A, Rao, Pk, Rapizzi, E, Raskauskas, P, Ratiglia, R, Ratnakaram, R, Rauser, Me, Regillo, C, Rehak, J, Reichel, E, Reid, Da, Rejmont, L, Rougier, Mb, Ribon, Ri, Ricarova, R, Rich, R, Riley, A, Ripandelli, G, Rishi, E, Rivett, K, Rogers, A, Romanet, Jp, Rosa, Pj, Rosberger, D, Rose, S, Rosenfeld, P, Ross, Rr, Rotberg, M, Roth, Cb, Roth, D, Rubaltelli, D, Rubsamen, P, Ruby, A, Ruiz Moreno JM, Ruiz, R, Russell Gonder, J, Russell, M, Ryu, Jw, Sachs, H, Sadda, S, Safar, A, Salinas, C, Sall, K, Samad, A, Samkova, K, Sanders, J, Sandhu, R, Sandhu, Ss, Sandner, D, Sanislo, Sr, Sartani, G, Saviano, S, Savy, O, Schechter, Ba, Schenker, Hi, Schiff, W, Schlichtenbrede, F, Schneider, B, Schneider, L, Schneiderman, T, Schocket, L, Schoenherr, U, Schoenleber, D, Scholl, Hp, Schreiber, J, Schwartz, Sd, Sears, J, Sedlakova, J, Seery, C, Sell, C, Shah, G, Shapiro, M, Sharma, A, Sheidow, T, Sheu, Sj, Sheufele, T, Shukla, D, Siewec Proscinska, J, Silva, Er, Singer, M, Singer, S, Singerman, Lj, Singh, M, Siow, Yc, Sipperley, Jo, Sivaprasad, S, Sjaarda, R, Snyder, W, Sobrin, L, Sodi, A, Solomon, S, Sonkin, P, Soubrane, G, Soucek, P, Spirn, B, Srivastava, S, Stannard, K, Staurenghi, G, Steinmetz, R, Stepien, K, Stern, W, Stevenson, Od, Stewart, D, Stewart, J, Stolba, U, Stoller, G, Stone, C, Stout, Jt, Stringfellow, G, Studnicka, J, Suarez Figueroa, M, Sung, J, Susini, A, Syracuse, R, Szaflik, J, Tabandeh, H, Tadayoni, R, Takahashi, Wy, Taleb, Ac, Talks, Sj, Tamayo, L, Tan, M, Taney, B, Tarnawska, D, Tassinari, G, Taylor, J, Telander, D, Territo, C, Thomas, El, Thomas, M, Thompson, Jt, Thompson, Ws, Tiedeman, Js, Topping, T, Trese, M, Truong, S, Tsang, Cw, Tufail, A, Ufret Vincenty, R, Uhmannova, R, 2nd, Ulanski L., Ulinska, M, Urminsky, J, Uy, H, Vaishnav, H, Varano, M, Vavvas, D, Vega Sanz BF, Veloso, A, Vicha, I, Viola, F, Visser, L, Vlkova, E, Voelker, M, Volkert, D, Vossmerbaumer, U, Vu, C, Vyas, S, Wald, Kj, Walker, J, Walter, A, Wang, R, Wasiak, K, Watt, Dr, Weger, M, 3rd, Weidman F., Weinberger, D, Weisz, Jm, 3rd, Wells J., Wheatley, M, Wickremasingh, S, Wiegand, T, Wieland, M, Will, D, Williams, G, Williams, Rg, Wilson, D, Win, Ph, Wing, Gl, Wirostko, W, Wirthlin, R, Wong, Al, Wong, T, Woo, J, Wu, Tt, Wylegala, E, Yan, J, Yang, Ch, Yang, Cm, Yang, Y, Yang, Yc, Yarian, D, Yates, P, Yedavally, S, Yoken, J, Young, L, Young, S, Zago, Rj, Zakov, Z, Zaras, M, Zegarra, H, Ziemianski, M, Zimmer Galler, I, Zourdani, A, and Zur, C.

Published
2011

45. Randomized, Sham-Controlled Trial of Dexamethasone Intravitreal Implant in Patients with Macular Edema Due to Retinal Vein Occlusion

Author

Haller, Ja, Bandello, F, Belfort R., Jr, Blumenkranz, Ms, Gillies, M, Heier, J, Loewenstein, A, Yoon, Yh, Jacques, Ml, Jiao, J, Li, Xy, Whitcup, Sm, OZURDEX GENEVA Study Group, Aaberg, Tm, Abraham, P, Abujamra, S, Acton, J, Adamczyk Ludyga, A, Adenwalla, M, Agahigian, Dd, Agoas, V, Aguilar Mendoza, M, Aisenbrey, S, Alam, S, Albiani, D, Alexandrescu, B, Alfaiate, Mm, Allam, S, Almeida, Hp, Anagnoste, S, Anand, R, Anderson, N, Antoszyk, A, Armogan, N, Arnold, J, Ash, D, Atlas, Wg, Augustin, Ja, de Avila MP, Awh, C, Azzolini, C, Babkova, B, Bakri, Sj, Banach, Mj, Barak, A, Barile, G, Barker, D, Barnard, T, Bartz Schmidt KU, Parodi, Mb, Baumal, C, Bedrich, P, Beer, P, Mattos RB Jr, Bellini, L, Benner, J, Benson, W, Benz, M, Berger, B, Bergren, R, Bharadwaj, A, Bhavan, S, Bhavsar, A, Binder, S, Biondi, A, Bishop, F, Blair, N, Blinder, K, Blumenkranz, M, Bohm, A, Boldrey, Ee, Bornfeld, N, Borrillo, Jl, Boyer, D, Bradford, R, Bridges, W, Brigatti, L, Briggs, M, Brooks HL Jr, Brown, D, Browning, A, Browning, D, Brunner, S, Brunnerova, R, Renata, Js, Brydak Godowska, J, Buettner, H, Burns, J, Burrows, Af, Busbee, B, Butner, R, Butter, J, Byrnes, G, Callahan, C, Campochiaro, P, Cano Hildalgo RA, Canziani, T, Capone, A, Carmichael, T, Carnevale, K, Casella, Am, Casey, R, Castanheira Dinis, A, Celis, B, Chambers, R, Chang, S, Chang, Yh, Chechik, D, Chee, Sp, Chen, E, Chen, Jt, Chen, Sn, Chen, S, Cheng, B, Chiquet, C, Chong, K, Chong, Lp, Chong, V, Chou, T, Chow, V, Chrapek, O, Chu, T, Chua, J, Chun, D, Chung, Hw, Cialdini, Ap, Ciancas, E, Cihelkova, I, Cisiecki, S, Clark, W, Cleary, T, Coco, R, Codenotti, M, Cohen, Bz, Cohen, Ja, Cohen, J, Connolly, B, Conway, B, Cook, H, Cooper, B, Coors, L, Corwin, J, Costa, Jr, Cottrell, D, Couvillion, S, Craig, J, Cruess, A, Cupo, G, Dabbs, T, Danesh, S, Davidorf, F, Davis, J, De Cilla, S, De Fazio, R, de la Fuente MA, de la Rua ER, De Mattia, M, Deen, A, Del Priore, L, Delyfer, Mn, Deuter, C, Devadason, Ds, Devenyi, R, D'Heurle, D, Dickinson, J, Doft, B, Dooner, J, Doubell, D, Downie, J, Drenser, K, Dreyer, R, D'Sousa, Y, Du, T, Duarte, L, Dubiner, Hb, Dubovy, S, Dubska, Z, Dugel, P, Dunn, W, Dusova, J, Dvorak, J, Dyer, D, Dziegielewska, K, Earl, M, Egan, C, Eichenbaum, D, Eifrig, C, Ells, A, El Shabrawi, Y, Elsherbiny, S, Engel, H, Engelbrecht, N, Ernest, J, Essex, R, Eter, N, Evans, R, Fakadej, A, Falcone, P, Fan, D, Fan, Jt, Farah, Me, Farah, S, Feiner, L, Feldman, Rm, Ferencz, J, Fernandez Vega Sanz, A, Ferreira, Jl, Figueira, J, Fineman, M, Fiser, I, Fish, G, Fish, Rh, Fishburne, B, Fisher, Sj, Fitzsimons, R, Flaxel, C, Fletcher, E, Flores Aguilar, M, Florez, S, Flynn, H, Fogarty, S, Folgado, A, Foster, Bs, Fox, Gm, Frambach, D, Fransen, S, Fraser Bell, S, Frederick, A, Freeman, W, Freisberg, L, Friedman, E, Friedman, L, Fucik, M, Fuller, Dg, Gaitan, J, Gallemore, R, Gallogly, P, Garcia Arumi, J, Garg, S, Garretson, B, Gastaud, P, Gaudric, A, Gawrilow, P, Gehlbach, Pl, Geyer, O, Ghuman, At, Giansanti, F, Gil, Al, Gilbert, Hd, Girmens, Jf, Giubilato, A, Glacet Bernard, A, Glaser, D, Glatzer, R, Goldstein, D, Gomes, Am, Gon Yu, H, Gonçalves, Fp, Gonzales, C, Googe, J, Gopal, L, Gordon, A, Gous, P, Grand, M, Grandao Magro PC, Granero Riano, M, Grassi, M, Green, J, Green, S, Gregor, Z, Gregori, N, Grizzard, Ws, Groenewald, C, Gross, Jg, Gross, Ne, Gruber, A, Grutow, G, Guillet, E, Gyorgyova, D, Haas, A, Haas, K, Hadden, P, Hagemann, L, Hainsworth, D, Haivala, D, Haller, J, Halperin, L, Hamer, P, Hammer, M, Han, D, Handa, Jt, Handelman, I, Handza, J, Harder, B, Harding, S, Hariprasad, Sm, Hartley, K, Hartman, P, Hartnett, Me, Harvey, P, Hassan, T, Headon, M, Hejsek, L, Higgins, P, Hillenkamp, J, Ho, A, Ho, T, Holekamp, N, Holz, E, Holz, F, Hooper, P, Hopkins, Jj, Hoskin Mott, A, Hoskins, J, Hrisomalos, N, Hsu, J, 3rd, Hubbard B., Hudson, H, Hughes, E, Hunt, A, Hunyor, A, Hwang, T, Hwang, Jf, Ibarra, M, Incarnato, N, Inhetvin Hutter, C, Introini, U, Isaacs, T, Islam, N, Iyer, Mn, Jablonski, C, Jack, Rl, Jager, R, Jahn, C, Jao, C, Jehan, F, Jonas, J, Joseph, D, Joshi, M, Jost, B, Jurklies, B, Kaincova, I, Kaiser, P, Kaiser, R, Kalvodova, B, Kamppeter, B, Kanann, Nb, Kang, K, Katz, Rs, Kaushal, S, Kecik, D, Kellaway, J, Kelly, K, Kelly, S, Khan, J, Kherani, A, Kim, R, Kim, I, Kim, J, Kim, Jg, Kim, N, Kim, Tw, Kingsley, R, Klein, R, Klemperer, I, Kociecki, J, Korbasova, M, Korda, V, Korobelnik, Jf, Koshy, Z, Kostamaa, H, Kovach, J, Kozak, I, Kozousek, V, Krasny, J, Kreiger, A, Krivosic, V, Krug JV Jr, Kruger, L, Kunimoto, D, Kuppermann, Bd, Kurtz, R, Kuznik Borkowska, A, Lai, J, Lai, W, Lake, S, Lalwani, G, Lam, Wc, Lanning, Rc, Lanzetta, Paolo, Lara, W, Larrison, Wi, Lattanzio, R, Lavina, A, Lavinsky, J, Lazzaroni, F, Lee, E, Lee, Jy, Lee, M, Lee, Sy, Lee, V, Leff, S, Lehr, J, Lenfesty, P, Leonard, R, Levine, A, Levitan, M, Lewis, H, Liew, S, Lim, J, Lim, R, Lin, R, Lip, Pl, Liu, J, Lobes, La, Loose, I, Lottenberg, Cl, Loutchkina, D, Lu, Dw, Lubczynska, A, Lujan, B, Lyssek Boron, A, Ma, C, Ma, P, Maberley, D, Maccumber, M, Madhusudhana, Kc, Madreperla, S, Magee, M, Magolan, J, Maia Ode O., Jr, Maia, A, Majji, A, Malthieu, D, Mango, C, Marmor, M, Marques, L, Martin, D, Martinez, Ja, Massaoutis, P, Mathur, R, Mattioli, S, Maturi, Rk, Mazur Michalek, I, Mcallister, I, Mccabe, F, Mccannel, Ca, Mcgimpsey, S, Mchugh, Jd, Mckibbin, M, McLean WC Jr, Mcmillan, T, Meireles, R, de Melo CS, Menchini, U, Meredith, T, Merrill, P, Mian, U, Michels, M, Midena, E, Mieler, Wf, Migliavacca, L, Miller, D, Miller, J, Mincey, G, Mitchell, P, Mizubuti, Sk, Mohamed, S, Mohammed, M, Moinfar, N, Moisseiev, J, Mones, J, Montemayor Lobo, R, Montero, J, de Moraes NI, Moreira CA Jr, Morely, M, Moreno, Jm, Moron, Jt, Morrison, Vl, Morse, L, Moshfeghi, A, Moshfeghi, D, Muccioli, C, Munshi, V, Murthy, Rc, Naing, T, Nair, R, Nascimento, J, Nascimento, Vp, Nawrocka, Z, Nawrocki, J, Newell, C, Newsom, R, Nguyen, J, Nguyen, Q, Nguyen, Rl, Nichols, J, Nilanjana, D, Noguchi, B, Noorily, S, Novack, R, Novak, M, Novalis, G, O'Brien, D, Offermann, I, Oguido, Ap, Oh, K, Okruszko, A, de Oliveira TL, Oliver, S, Ong, S, Orellana, J, Orzalesi, N, O'Toole, L, Ovando, Y, Paccione, J, Pach, J, Packo, K, Packowska, Ma, Palmer, J, Palmer, H, Palombi, K, Papp, A, Paques, M, Paranhos A., Jr, Park, D, Park, Ri, Park, S, Parke, D, Pastor Jimeno JC, Patel, S, Patra, S, Pavan, Pr, Pearce, I, Pecold, K, Pedio, M, Peh, Kk, Pelosini, L, Pendergast, S, Perez, Br, Perez Ortiz DJ, Perkins, S, Peters, M, Pheasant, T, Pilat, J, Pilotto, E, Piltz Seymour, J, Pirracchio, A, Pollack, A, Portella, E, Pracharova, Z, Prati, M, Prensky, Jg, Preston, R, Prieto, F, Puls, S, Purohit, Ar, Quintao, T, Rahhal, F, Rahman, W, Ramos, Ar, Ramsey, S, Rani, A, Rao, Pk, Rapizzi, E, Raskauskas, P, Ratiglia, R, Ratnakaram, R, Rauser, Me, Regillo, C, Rehak, J, Reichel, E, Reid, Da, Rejmont, L, Renaud Rougier MB, Ribon, Ri, Ricarova, R, Rich, R, Riley, A, Ripandelli, G, Rishi, E, Rivett, K, Rogers, A, Romanet, Jp, Rosa, Pj, Rosberger, D, Rose, S, Rosenfeld, P, Ross, Rr, Rotberg, M, Roth, Cb, Roth, D, Rubaltelli, D, Rubsamen, P, Ruby, A, Ruiz Moreno JM, Ruiz, R, Russell Gonder, J, Russell, M, Ryu, Jw, Sachs, H, Sadda, S, Safar, A, Salinas, C, Sall, K, Samad, A, Samkova, K, Sanders, J, Sandhu, R, Sandhu, Ss, Sandner, D, Sanislo, Sr, Sartani, G, Saviano, S, Savy, O, Schechter, Ba, Schenker, Hi, Schiff, W, Schlichtenbrede, F, Schneider, B, Schneider, L, Schneiderman, T, Schocket, L, Schoenherr, Schoenleber, D, Scholl, Hp, Schreiber, J, Schwartz, Sd, Sears, J, Sedlakova, J, Seery, C, Sell, C, Shah, G, Shapiro, M, Sharma, A, Sheidow, T, Sheu, Sj, Sheufele, T, Shukla, D, Siewec Proscinska, J, Silva, E, Singer, M, Singer, S, Singerman, Lj, Singh, M, Siow, Yc, Sipperley, Jo, Sivaprasad, S, Sjaarda, R, Snyder, W, Sobrin, L, Sodi, A, Solomon, S, Sonkin, P, Soubrane, G, Gisèle, P, Spirn, B, Srivastava, S, Stannard, K, Staurenghi, G, Steinmetz, R, Stepien, K, Stern, W, Stevenson, Od, Stewart, D, Stolba, U, Stoller, G, Stone, C, Stout, Jt, Stringfellow, G, Studnicka, J, Suarez Figueroa, M, Sung, J, Susini, A, Syracuse, R, Szaflik, J, Szlechter, M, Tabandeh, H, Tadayoni, R, Takahashi, Wy, Taleb, Ac, Talks, Sj, Tamayo, L, Tan, M, Taney, B, Tarnawska, D, Tassinari, G, Taylor, J, Telander, D, Territo, C, Thomas, M, Thompson, Jt, Thompson, Ws, Tiedeman, Js, Topping, T, Trese, M, Truong, S, Tsang, Cw, Tufail, T, Ufret Vincenty, R, Uhmannova, R, 2nd, Ulanski L., Ulinska, M, Urminsky, J, Uy, H, Vaishnav, H, Varano, M, Vavvas, D, Vega Sanz BF, Veloso, A, Vicha, I, Viola, F, Visser, L, Vlkova, E, Voelker, M, Volkert, D, Vossmerbaumer, U, Vu, C, Vyas, S, Walker, J, Walter, A, Andreas, R, Wasiak, K, Watt, Dr, Weger, M, 3rd, Weidman F., Weinberger, D, Weisz, Jm, 3rd, Wells J., Wheatley, M, Wickremasingh, S, Wiegand, T, Wieland, M, Will, D, Williams, G, Williams, Rg, Wilson, D, Win, Ph, Wing, Gl, Wirostko, W, Wirthlin, R, Wong, Al, Wong, T, Woo, J, Wu, Tt, Wylegala, E, Yan, J, Yang, Ch, Yang, Cm, Yang, Y, Yang, Yc, Yarian, D, Yates, P, Yedavally, S, Yoken, J, Young, L, Young, S, Zago, Rj, Zakov, Z, Zaras, M, Zegarra, H, Ziemianski, M, Zimmer Galler, I, Zourdani, A, and Zur, C.

Published
2010

46. Expression of angiogenesis-related biomarkers in thymic epithelial tumors (TET)

Author

Marino, M, Lattanzio, R, Lauriola, L, Martucci, R, Sioletic, S, Gallo, E, Palmieri, G, Evoli, A, Granone, P, Palestro, Giorgio, Chiarle, Roberto, Barreca, A, Pich, Achille, Remotti, D, Pisa, R, Martelli, M, Truini, M, Ascani, S, Ruco, L, Rendina, Ea, Tunesi, G, Antimi, M, Lalle, M, Carlini, S, Facciolo, F, and Piantelli, M.

Subjects
angiogenesis, biomarkers, thymic epithelial tumors
Published
2010

47. Colonoscopy practice in Italy: a prospective survey on behalf of the Italian Association of Hospital Gastroenterologists

Author

Radaelli, F, Meucci, G, Minoli, G, Italian Association of Hospital Gastroenterologists Alluminio, P, Amuso, M, Angelini, G, Anti, M, Baldi, F, Balzana, M, Barberani, F, Bargiggia, S, Barresi, G, Bedosti, M, Belmonte, A, Benedetti, A, Benedetti, E, Benini, M, Beretta, L, Beretta, P, Fontana, A, Mauro, B, Bianco, R, Bierti, L, Bigazzi, U, Boccia, S, Bonello, F, Boscarino, S, Bottini, E, Bresci, G, Briglia, U, Brunelli, E, Buggiani, D, Calandra, A, Candidi, A, Caneschi, F, Cannizzaro, R, Cappuccino, V, Caputi, O, Cardelli, A, Caronia, V, Cattuto, C, Cestari, E, Chilovi, F, Cifatte, D, Ciliberto, E, Cimino, F, Cipolletta, V, Cirillo, M, Cocozza, U, Colantuoni, E, Coli, A, Colombo, E, Comin, U, Conti, W, Cortini, C, Criscione, S, Crotta, S, Cutela, P, D'Imperio, N, Dalia, G, Dall'Oglio, L, Dal Pane, M, Dante, P, Dato, D, Dattola, L, De Bernardin, M, De Boni, M, De Conca, V, Dell'Amico, I, Dell'Anna, A, Della Spoletina, A, Delogu, G, Del Piano, M, Di Cicco, M, Di Filippo, G, Di Giorgio, P, Di Mitri, R, Di Piero, A, Di Piramo, D, Di Todaro, E, Dicillo, M, Dodero, C, Doldo, P, Drago, D, Dubla, G, Dughera, L, Dusio, P, Ederle, A, Evola, M, Fachinetti, F, Faraldo, G, Farroni, F, Fasoli, R, Ferrara, A, Ferrari, A, Ferrari, C, Ferraris, L, Ferraris, R, Ferrini, G, Ferrini, L, Foco, A, Forte, G, Francavilla, A, Franzè, A, Fregoni, D, Frieri, Giuseppe, Gaia, E, Galasso, F, Galgani, P, Gamberucci, G, Gatti, L, Gatti, M, Gemme, C, Ghione, S, Ghisotti, E, Giaccari, S, Giannelli, C, Giorcelli, V, Giuri, G, Giurissa, A, Grassini, M, Grasso, G, Graziani, Mg, Gualtiero, J, Gullini, S, Gullotta, R, Iaquinto, G, Jacoponi, S, Laganà, S, Lamanda, R, Lattanzio, R, Lauri, A, Lecis, Pe, Ledda, P, Leone, S, Ligas, E, Liuzzi, N, Lochis, D, Longaroni, M, Lorenzini, I, Loriga, P, Lussu, B, Luzza, F, Madia, D, Malfitana, G, Mallozzi, Ef, Mancini, S, Mangiarotti, R, Manildo, M, Manneschi, L, Marcon, V, Marino, M, Marrucci, A, Martines, H, Maruelli, A, Massari, M, Massidda, C, Mauri, R, Mazzarello, Pl, Mazzolla, E, Mellone, C, Meloni, M, Merighi, A, Mescia, P, Michetti, P, Milan, L, Milandri, G, Miori, G, Monastra, S, Moncelli, G, Monica, F, Montanaro, F, Moretti, M, Morini, S, Mosca, F, Mosca, D, Moschetta, R, Mura, G, Naim, G, Nardella, G, Natale, A, Negrini, F, Niccoli, G, Nova, A, Occhipinti, P, Ocera, S, Orlandi, Pg, Orsini, O, Pagani, E, Paliani, O, Pardocchi, D, Parodi, Cm, Pasini, D, Pasquale, L, Pasquali, L, Paterlini, A, Pellecchia, A, Pera, A, Perego, M, Perugini, B, Petracca, F, Peyre, S, Piccoli, F, Pilati, S, Pierucci, E, Pizzetti, P, Pizzolato, S, Polimeni, F, Politano, S, Polo, S, Portaluri, F, Prada, A, Privitera, U, Quaranta, S, Raguzzi, I, Ravelli, P, Recchia, S, Revetria, P, Ripoli, D, Rocca, F, Roda, E, Rogheto, M, Rosati, S, Rosina, F, Rossi, A, Rotolo, A, Sabadini, Gr, Saffiotti, O, Salerno, D, Sanesi, A, Sanna, S, Saracco, G, Savarino, V, Scaccianoce, G, Scarpulla, G, Schiffino, L, Schippa, P, Sebastiani, P, Servillo, F, Sgarbi, D, Sigillito, D, Snider, L, Sorrentini, I, Spadaccini, A, Sticchi, V, Sturniolo, Gc, Suriani, R, Tammaro, L, Tarchi, F, Tasini, E, Tebaldi, M, Terruzzi, V, Testoni, Pa, Tonelli, F, Trapè, R, Triossi, O, Usai, P, Usula, E, Vecchi, M, Vecchi, E, Ventrucci, M, Viero, K, Virgilio, C, Viviani, G, Zampaletta, U, and Zilli, M.

Subjects
Colonoscopy, Endoscopy
Published
2008

48. Evolution of initial retinal microangiopathy in pregnant diabetic women

Author

BANDELLO , FRANCESCO, Brancato R, Lattanzio R, Maestranzi G, Moretti G, Castiglioni MT, DAmbrosio P, Dozio N, Garancini P., Bandello, Francesco, Brancato, R, Lattanzio, R, Maestranzi, G, Moretti, G, Castiglioni, Mt, Dambrosio, P, Dozio, N, and Garancini, P.

Published
1997

49. Relationship between a point mutation of the alpha-adducin and left ventricular mass

Author

Stella P, Cusi D, Barlassina C, Righetti M, MANUNTA, PAOLO, Rivera R, Lanzani C, Azzani T, Citterio L, Maestranzi G, Lattanzio R, Bianchi G., BANDELLO , FRANCESCO, Stella, P, Cusi, D, Barlassina, C, Righetti, M, Manunta, Paolo, Rivera, R, Lanzani, C, Azzani, T, Citterio, L, Maestranzi, G, Lattanzio, R, Bandello, Francesco, and Bianchi, G.

Published
1996

Catalog

Books, media, physical & digital resources
See catalog results